Home  |  Contact

Cellosaurus RD (CVCL_1649)

[Text version]

Cell line name RD
Synonyms R D; RD-2; RD 2; 130T; 130-T; 130 T; TE-32; TE 32; TE32; TE 32.T; Te 32.T
Accession CVCL_1649
Secondary accession CVCL_S332
Resource Identification Initiative To cite this cell line use: RD (RRID:CVCL_1649)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 23 hours (PubMed=20922763).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Cell surface proteome.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for NRAS p.Gln61His (c.183A>T) (PubMed=3158613; PubMed=12068308; PubMed=22142829; ATCC).
Homozygous for TP53 p.Arg248Trp (c.742C>T) (PubMed=2216456; ATCC).
Genome ancestry Source: PubMed=30894373

Origin% genome
African3.96
Native American0
East Asian, North4.77
East Asian, South0
South Asian0
European, North53.65
European, South37.61
Disease Embryonal rhabdomyosarcoma (NCIt: C8971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_LM95 (3AB-OS)CVCL_0350 (IN157)CVCL_XD25 (RD-Luc)
CVCL_IU94 (RD/12)CVCL_VH40 (RD/15)CVCL_IU87 (RD/18)
CVCL_VH41 (RD/19)CVCL_VH39 (RD/7)CVCL_DP30 (RD.TG6)
CVCL_1756 (TE 671)
Sex of cell Female
Age at sampling 7Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; COG; ECACC; JCRB; KCLB; PubMed=20922763; PubMed=21948088

Markers:
AmelogeninX
CSF1PO10,11
D2S133817,23
D3S135815,17
D5S81811
D7S8208,12
D8S117911,15
D13S31713
D16S53910,11
D18S5113,18
D19S43311,14
D21S1128,29
FGA20,21
Penta D11,13
Penta E12
TH019.3
TPOX9
vWA18

Run an STR similarity search on this cell line
Web pages http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://en.vircell.com/products/rd-cell-line/
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=293
http://www.cellresource.cn/fdetail.aspx?id=451
http://www.cellresource.cn/fdetail.aspx?id=615
http://www.cellresource.cn/fdetail.aspx?id=1972
Publications

PubMed=4241949; DOI=10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M
McAllister R.M., Melnyk J., Finkelstein J.Z., Adams E.C. Jr., Gardner M.B.
Cultivation in vitro of cells derived from a human rhabdomyosarcoma.
Cancer 24:520-526(1969)

PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=3158613; DOI=10.1002/ijc.2910350513
Chardin P., Yeramian P., Madaule P., Tavitian A.
N-ras gene activation in the RD human rhabdomyosarcoma cell line.
Int. J. Cancer 35:647-652(1985)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=2216456
Stratton M.R., Moss S., Warren W., Patterson H., Clark J., Fisher C., Fletcher C.D.M., Ball A., Thomas M., Gusterson B.A., Cooper C.S.
Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene.
Oncogene 5:1297-1301(1990)

PubMed=2302710
Ozkaynak M.F., Nolta J., Parkman R.
In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.
Cancer Res. 50:1455-1458(1990)

PubMed=1917385
Lollini P.-L., De Giovanni C., Landuzzi L., Nicoletti G., Scotlandi K., Nanni P.
Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells.
Invasion Metastasis 11:116-124(1991)

PubMed=8275086; DOI=10.1038/ng1193-230
Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J. III, Emanuel B.S., Rovera G., Barr F.G.
Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.
Nat. Genet. 5:230-235(1993)

PubMed=8383879; DOI=10.1126/science.8383879
Tapscott S.J., Thayer M.J., Weintraub H.
Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
Science 259:1450-1453(1993)

PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)

PubMed=19235922; DOI=10.1002/gcc.20655
Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B.M., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J.M.
Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
Genes Chromosomes Cancer 48:455-467(2009)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=21948088; DOI=10.1158/1078-0432.CCR-11-1004
Belyea B.C., Naini S., Bentley R.C., Linardic C.M.
Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
Clin. Cancer Res. 17:7324-7336(2011)

PubMed=22142829; DOI=10.1158/1078-0432.CCR-11-2056
Shukla N., Ameur N., Yilmaz I., Nafa K., Lau C.-Y., Marchetti A., Borsu L., Barr F.G., Ladanyi M.
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.
Clin. Cancer Res. 18:748-757(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22541669; DOI=10.1186/2044-5040-2-7
Macquarrie K.L., Yao Z., Young J.M., Cao Y., Tapscott S.J.
miR-206 integrates multiple components of differentiation pathways to control the transition from growth to differentiation in rhabdomyosarcoma cells.
Skelet. Muscle 2:7-7(2012)

PubMed=23578105; DOI=10.1111/cas.12173
Nishimura R., Takita J., Sato-Otsubo A., Kato M., Koh K., Hanada R., Tanaka Y., Kato K., Maeda D., Fukayama M., Sanada M., Hayashi Y., Ogawa S.
Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.
Cancer Sci. 104:856-864(2013)

PubMed=23882450; DOI=10.3389/fonc.2013.00183
Hinson A.R.P., Jones R., Crose L.E.S., Belyea B.C., Barr F.G., Linardic C.M.
Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.
Front. Oncol. 3:183-183(2013)

PubMed=25894527; DOI=10.1371/journal.pone.0121314
Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F., Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R., Schmidt A., Mirkowska P., Hartlova A., Van Eyk J.E., Bourquin J.-P., Aebersold R., Boheler K.R., Zandstra P., Wollscheid B.
A mass spectrometric-derived cell surface protein atlas.
PLoS ONE 10:E0121314-E0121314(2015)

PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074
Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J.
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Mol. Cancer Ther. 14:2452-2462(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

Cross-references
Cell line collections AddexBio; C0035001/4950
ATCC; CCL-136
ATCC; CRL-7713 - Discontinued
ATCC; CRL-7731 - Discontinued
ATCC; HTB-97 - Discontinued
BCRC; 60113
BCRJ; 0260
CCTCC; GDC0295
CLS; 300401/p527_RD
ECACC; 85111502
IZSLER; BS TCL 57
JCRB; JCRB9072
KCLB; 10136
Cell line databases/resources CLDB; cl4119
CLDB; cl4120
CLDB; cl4121
CLDB; cl4122
CLDB; cl4123
CLDB; cl4124
CLDB; cl4125
CLDB; cl4126
CLDB; cl4127
CCLE; RD_SOFT_TISSUE
CCRID; 3111C0001CCC000293
CCRID; 3111C0002000000079
CCRID; 3131C0001000700045
CCRID; 3142C0001000000321
Cell_Model_Passport; SIDM00847
Cosmic-CLP; 909264
DepMap; ACH-000169
GDSC; 909264
IGRhCellID; RD
LINCS_LDP; LCL-1411
Lonza; 1536
TOKU-E; 2986
Ontologies BTO; BTO:0005377
CLO; CLO_0008693
CLO; CLO_0008770
EFO; EFO_0002315
Biological sample resources BioSample; SAMN01821591
BioSample; SAMN01821716
BioSample; SAMN03472710
BioSample; SAMN10988441
Chemistry resources ChEMBL-Cells; CHEMBL3307547
ChEMBL-Targets; CHEMBL614144
PharmacoDB; RD_1296_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM185149
GEO; GSM186446
GEO; GSM219726
GEO; GSM887528
GEO; GSM888610
GEO; GSM1670368
GEO; GSM1676309
GEO; GSM1701643
Other Wikidata; Q54949532
Polymorphism and mutation databases Cosmic; 724833
Cosmic; 801358
Cosmic; 801760
Cosmic; 802045
Cosmic; 909264
Cosmic; 1037298
Cosmic; 1048111
Cosmic; 1097753
Cosmic; 1309330
Cosmic; 1509195
Cosmic; 1620036
Cosmic; 1718099
Cosmic; 2296987
Cosmic; 2301590
Cosmic; 2355912
IARC_TP53; 767
LiGeA; CCLE_882
Proteomic databases PRIDE; PXD000589
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number30